Heming Lu*†1, Yuying Wu‡1, Xu Liu†, Huixian Huang†, Hailan Jiang†, Chaohua Zhu†, Yuping Man§, Zhaohong Chen†, Xianfeng Long†, Qiang Pang†, Luxing Peng†, Xianglong Li†, Junzhao Gu†, Shan Deng†, Ligang Xing*
Oncology Research, Vol.28, No.9, pp. 929-944, 2020, DOI:10.3727/096504021X16318716607908
Abstract This phase II randomized clinical trial aimed to assess the efficacy and toxicity of Endostar, an antiangiogenesis
inhibitor, combined with concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC).
Patients with LACC were randomly assigned to either CCRT plus Endostar (CCRT+E arm) or CCRT alone
(CCRT arm). All patients received pelvic intensity-modulated radiation therapy (IMRT) and brachytherapy.
Weekly cisplatin was administered concurrently with IMRT. Patients in the CCRT+E arm also received concurrent Endostar every 3 weeks for two cycles. The primary endpoint was progression-free survival (PFS)
and acute toxicities. The exploratory endpoint was the impact of vascular endothelial growth factor… More >
Login
Register
